Join to View Full Profile
MGH Cancer Center55 Street, Jackson 904BBoston, MA 02114
Phone+1 617-726-9372
Fax+1 844-542-5959
Dr. Jenkins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Russell Jenkins is an oncology specialist based in Boston, MA, with subspecialties in hematologic oncology and melanoma. He completed his fellowship in hematology and medical oncology at Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute from 2014 to 2018. His earlier training includes an internal medicine internship and residency at Massachusetts General Hospital. Dr. Jenkins earned his M.D. and Ph.D. in 2012 from the Medical University of South Carolina. His expertise includes immunotherapy and melanoma, with several publications focusing on therapeutic strategies and challenges in oncology.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2018
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2013 - 2014- Mass General Brigham/Massachusetts General HospitalInternship, Internal Medicine, 2012 - 2013
Medical University of South CarolinaClass of 2012
Certifications & Licensure
MA State Medical License 2015 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade.Ana Carolina M Domingues, Soraia B de Oliveira, Nayara G Tessarollo, Ana Paula Lepique, Otavio Rodrigues
Molecular Therapy. Oncology. 2025-03-20 - TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids.Yi Sun, Luke Maggs, Apekshya Panda, Samuel J Wright, Angelina M Cicerchia
Cancer Immunology Research. 2025-02-03 - Real-world data confirms limited efficacy of dual programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 immune checkpoint blockade in acral l...David X Zheng, Russell W Jenkins
The British Journal of Dermatology. 2025-01-24
Journal Articles
- Tumor Innate Immunity Primed by Specific Interferon-Stimulated Endogenous RetrovirusesScott Rodig, Ewa Sicinska, Thanh Uyen Barbie, David Allen Barbie, Russell William Jenkins, Ravindra Uppaluri, Rohit Thummalapalli, Jacob Sands, Nature
Press Mentions
Study Identifies TBK1 as Key to Overcoming CAR T ResistanceJanuary 9th, 2025
Melanoma Research Alliance Announces $8.2 Million for 33 Grant Awards to Advance Melanoma ResearchApril 30th, 2019
Grant Support
- Dissecting the tumor-intrinsic and -extrinsic roles of TBK1 in tumor immunityMASSACHUSETTS GENERAL HOSPITAL2023–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
